Experimental combo targets leukemia by starving cancer cells
NCT ID NCT05001828
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called ADI-PEG 20 added to two standard chemotherapy drugs (venetoclax and azacitidine) for people with acute myeloid leukemia (AML). The study includes 38 adults with either relapsed/refractory AML or newly diagnosed AML who cannot have intensive chemo. The main goal is to find the safest dose and look for early signs that the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADI-PEG 20 (a drug that breaks down arginine, an amino acid cancer cells need) combined with venetoclax and azacitidine (standard chemotherapy drugs)
What this could lead to
If it works, this could improve treatment options for people with acute myeloid leukemia, especially those who cannot tolerate intensive chemotherapy.
What could go wrong
This is a very early, small Phase 1 trial focused on safety and dosing, not proof of effectiveness. The combination may cause side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States